MPOXED

Prior Mpox Infection Results in More Durable Protection Than MVA-BN Vaccination

January 13, 2026

New findings reported in The Lancet Infectious Diseases complicate assumptions about mpox immunity. Among smallpox-naive adults, prior mpox infection produced stronger and more durable immune memory than vaccination with the MVA-BN vaccine. As breakthrough infections increase, these data suggest population-level immunity may erode faster than anticipated. While vaccination remains essential for prevention, especially during outbreaks, the results underscore the need to reassess durability, booster strategies, and how natural infection data should inform long-term mpox control planning.

Mpox Clade Ib Arrives in Mexico

January 13, 2026

Mexico’s first confirmed mpox case caused by clade Ib is a reminder that viral evolution and global mobility remain tightly linked. While there is no evidence of community transmission, the detection of a more virulent clade previously concentrated in Africa underscores the importance of vigilant surveillance beyond endemic regions. The World Health Organization and national health authorities are right to emphasize monitoring, rapid case identification, and vaccination readiness. Imported cases may be clinically manageable in high-resource settings, but their appearance signals that mpox remains a global concern that demands sustained attention, not episodic alarm.

Will Evolving Mpox Clades Cause Global Outbreaks Again

January 9, 2026

Mpox has faded from headlines, but it has not faded from reality. With sustained transmission in Africa, emerging recombinant strains, and sporadic imported cases elsewhere, the virus continues to evolve under the radar. Evidence summarized in Nature underscores how clade diversity, sexual transmission dynamics, and viral persistence complicate control efforts. The appearance of a recombinant strain and unanswered questions about fertility impacts should sharpen global attention. Surveillance, vaccination of at-risk populations, and continued research are not precautionary luxuries. They are the minimum requirements to prevent mpox from re-emerging as a broader and more adaptive global threat.

Emergent BioSolutions, PANTHER Partner to Advance Africa CDC-Led MpOx Study

January 9, 2026

The Africa CDC-led MOSA trial marks a necessary shift from emergency response to evidence-based mpox treatment. With more than 61,000 confirmed cases across Africa and no dedicated antiviral therapy, platform-adaptive trials like MOSA are overdue. The collaboration between Emergent BioSolutions, PANTHER, and Africa CDC demonstrates how global financing can align with regional leadership without displacing African scientific authority. Sustained support must now follow the data, ensuring expansion, transparency, and rapid translation of findings into access where mpox burden remains highest.

Traveler brings home a newly-evolved ‘hybrid’ mpox virus

January 7, 2026

The discovery of a hybrid mpox strain in England is a reminder that this virus is still adapting, even as public attention wanes. Detected in a traveler returning from Asia, the strain combines genetic material from two mpox lineages, underscoring ongoing viral evolution. More concerning is the simultaneous appearance of clade Ib infections in people without travel history, suggesting silent local transmission. With tens of thousands of confirmed cases globally, mpox is no longer an episodic threat but a persistent public health challenge. Vigilant surveillance, rapid genomic sequencing, and sustained prevention efforts remain essential to prevent incremental spread from becoming the next global crisis.

Prior Mpox Infection Results in More Durable Protection Than MVA-BN Vaccination

January 6, 2026

New evidence from a Belgian cohort study suggests that natural mpox infection generates more durable immune memory than vaccination with MVA-BN alone, raising important questions for long-term outbreak control. While vaccination remains critical for prevention and severity reduction, antibody levels in vaccinated individuals appear to wane faster than in those with prior infection. As breakthrough cases continue to occur, these findings highlight the need to reassess assumptions about population immunity, especially among younger, smallpox-naive cohorts. Policymakers and public health agencies must consider whether booster strategies or revised vaccination schedules will be required to sustain protection in the years ahead.

Mpox antibodies wane 2 years after infection or vaccination, study finds

January 6, 2026

A new study from Italy raises important questions about the durability of antibody-based immunity to mpox after infection or vaccination. Researchers found that neutralizing antibodies often decline to low or undetectable levels within two years, even among individuals previously vaccinated with Jynneos or infected with mpox. While prior infection appeared to confer more persistent antibody responses than vaccination alone, protection likely extends beyond measurable antibodies. Cellular immunity and immune memory from earlier smallpox vaccination may still offer meaningful defense. The full study is published in The Journal of Infectious Diseases and requires institutional or paid access, limiting independent review of underlying data.

Anchorage man tests positive for mpox, the first case in a year

December 26, 2025

A newly reported mpox case in Alaska serves as a reminder that the virus has not disappeared, even after the end of the U.S. public health emergency. While state officials believe this case is isolated and linked to exposure outside Alaska, it highlights how easily infectious diseases can cross borders. Public health messaging remains critical, particularly for individuals at higher risk, including those with multiple or anonymous sexual partners. Vaccination remains a highly effective preventive tool, and early testing is essential. Mpox may be rare in Alaska, but continued vigilance protects both individuals and the broader community.

Mpox Vaccine Donations Help Curtail Outbreaks in Africa

December 20, 2025

Mpox continues to pose a serious public health challenge across Africa, with more than 42,000 confirmed cases in 2025 driven by Clade I and Clade Ib transmission. While community spread persists in multiple countries, renewed vaccine donations offer cautious optimism. Shipments of MVA-BN vaccines to Liberia and Uganda underscore the importance of sustained international support and timely distribution. These efforts demonstrate that vaccination remains a critical tool for outbreak control, even as inequities in access persist. The evolving situation reinforces a clear lesson from recent years: global health security depends on early intervention, reliable supply chains, and continued investment in prevention, not complacency once headlines fade.

Reports show how mpox clade 1b spreads through non-sexual contact in DR Congo, Ireland

December 19, 2025

New evidence from the Democratic Republic of the Congo and Ireland underscores a critical shift in mpox clade 1b transmission. In Uvira, household spread, not sexual contact, drove infections, disproportionately affecting children living in crowded, resource-limited settings. Infant mortality, while lower than in clade 1a outbreaks, remains alarmingly high. Ireland’s first clade 1b cluster shows the virus can also spread through healthcare and household exposure in high-income countries. Together, these findings challenge narrow risk frameworks and highlight the urgent need for household-focused prevention, vaccination, nutrition support, and sustained global surveillance.

First case of mpox variant confirmed in Berlin

December 18, 2025

The first detection of mpox variant Ib in Berlin highlights the ongoing risk of cross-border transmission in an interconnected Europe. Although the case appears isolated and linked to travel and sexual contact, it underscores persistent vulnerabilities among unvaccinated individuals and the importance of targeted prevention. German authorities report no evidence of increased severity or sustained local spread, which is reassuring. Still, this case is a reminder that mpox has not disappeared. Continued surveillance, clear risk communication, and improved vaccine uptake among at-risk populations remain essential to prevent sporadic cases from becoming wider outbreaks.

From fear to hope: How DRC’s Equateur province turned the tide on mpox

December 16, 2025

The mpox outbreak in Equateur province tested the courage of frontline health workers and the resilience of the Democratic Republic of Congo’s health system. As fear and uncertainty gripped clinics in Mbandaka, nurses like Monique Mulo Itala continued caring for patients while fearing for their own families. The turning point came with coordinated international support that delivered vaccines, diagnostics, and infection control resources. The result was a dramatic reduction in cases and deaths. Equateur’s experience shows that when health workers are protected and communities are engaged, even severe outbreaks can be reversed.

El Paso reports first Mpox case of 2025, health officials launch contact tracing efforts

December 16, 2025

El Paso’s first confirmed Mpox case of 2025 is a reminder that the virus has not disappeared, even as public attention has shifted elsewhere. The city’s rapid response, including contact tracing and vaccine outreach, reflects lessons learned from prior outbreaks. Public health messaging has rightly emphasized that Mpox spreads through close skin-to-skin contact, not through the air, and that early recognition matters. For at-risk populations, vigilance, timely vaccination, and prompt medical evaluation remain essential. El Paso’s experience underscores that preparedness at the local level is critical to preventing isolated cases from becoming broader community transmission.

Spain reports first known human-to-human mpox clade 1b transmission outside Africa

December 11, 2025

The reported case of mpox clade 1b transmission in Spain without any travel link marks a critical warning for global public health. This case suggests that highly transmissible mpox strains can establish local human-to-human spread beyond endemic regions, even among vaccinated individuals. While vaccination remains essential for reducing severity, it is not a standalone safeguard against transmission. The finding underscores the need for vigilant surveillance, routine clade-specific testing, and rapid public health response in non-endemic countries. Mpox is no longer a distant threat. Preparedness, targeted vaccination, and community engagement must remain priorities even after emergency declarations are lifted.

Now is the time to launch mpox vaccine booster trials

December 11, 2025

The resurgence of mpox in major U.S. cities such as Los Angeles, New York, and Chicago underscores an urgent need for renewed public health research and action. With Clade I mpox now appearing in Los Angeles through local transmission, questions about booster vaccination are growing, yet data remain scarce. Despite evidence of strong initial protection from the two-dose Jynneos vaccine, the durability of immunity is still unclear. Federal leadership has waned, and vital studies on boosters remain unfunded. Empowering community-led research and funding clinical trials must become priorities to strengthen prevention, protect vulnerable populations, and prepare for sustained mpox circulation.

New virus strain found in UK for first time is 'precisely what experts feared'

December 10, 2025

The discovery of a recombinant mpox strain in the United Kingdom marks a worrying development in the ongoing evolution of the virus. Containing genetic material from both Clade Ib and Clade IIb, the new variant underscores how continued global transmission can drive viral adaptation. Experts warn that recombination could alter transmissibility, severity, or even affect diagnostic accuracy. While investigations are underway, the case highlights the urgent need for sustained vaccination, genomic surveillance, and international cooperation. As the UK Health Security Agency continues its analysis, early detection and proactive public health responses remain the best defenses against a rapidly adapting pathogen.

New hybrid mpox strain discovered in UK after US reports local spread

December 10, 2025

The detection of a recombinant mpox strain in the United Kingdom underscores the virus’s ongoing evolution and the importance of sustained genomic surveillance. The new variant, combining elements of clade I and clade II, signals that both lineages continue to circulate globally, raising the risk of more complex outbreaks. While health authorities emphasize that the discovery is not unexpected, it reinforces the need for robust monitoring, vaccination, and public awareness. As travel and localized transmission persist across continents, coordinated international vigilance remains essential to detect new mutations early and to prevent broader spread among vulnerable and unvaccinated populations.

A new mpox variant has been identified in the UK. Should we be worried?

December 9, 2025

The emergence of a hybrid mpox strain in the United Kingdom, combining clades I and II, marks a troubling milestone in the virus’s evolution. Experts warn that unchecked global transmission has created the conditions for such recombination, raising questions about future virulence and transmissibility. While the UK’s surveillance and vaccination systems are expected to contain this case, resource-limited countries remain highly vulnerable. This development underscores the need for sustained global vigilance, expanded genomic monitoring, and equitable vaccine access. Mpox’s continuing evolution is a reminder that delayed response and uneven preparedness invite new threats that no region can ignore.

New mutant mpox strain discovered in England — how concerned should people be?

December 9, 2025

The discovery of a recombinant mpox strain in England combining clades Ib and IIb underscores the ongoing evolution of this virus and the global gaps in containment. Public health experts, including Dr. Demetre Daskalakis, stress vigilance rather than panic, emphasizing the need for continued genomic surveillance and vaccination. The variant’s emergence highlights how persistent transmission enables viral adaptation and reinforces that mpox remains a global health concern. Vaccination, testing, and equitable access to care are critical tools to prevent new strains from taking hold, especially among vulnerable communities where past outbreaks have caused disproportionate impact.

New strain of mpox virus: What you need to know

December 9, 2025

The United Kingdom’s confirmation of a recombinant mpox virus underscores the ongoing evolution of this pathogen and the need for sustained global vigilance. The hybrid strain, formed from Clades Ib and IIb, emerged in a traveler returning from Asia and highlights how recombination can occur when multiple virus types circulate simultaneously. Experts stress that while this new variant poses no immediate heightened threat, continuous monitoring, vaccination, and laboratory analysis are critical to assess potential changes in transmissibility or virulence. The case serves as a reminder that mpox remains a dynamic global health concern requiring international cooperation and robust surveillance.

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

December 9, 2025

The Democratic Republic of the Congo’s approval for NanoViricides to begin its Phase II clinical trial of NV-387 marks a key step in advancing a potential antiviral for mpox. With no proven effective treatments and recent failures of tecovirimat and brincidofovir, NV-387 offers a novel host-mimetic approach that targets viral binding to human cell receptors rather than viral proteins, reducing the likelihood of resistance. The drug’s broad-spectrum design, proven animal efficacy, and oral formulation make it promising for outbreak-prone regions like Central Africa. If successful, NV-387 could redefine antiviral therapy and strengthen pandemic preparedness against orthopoxvirus threats.

Warning issued after new mpox strain identified in England

December 8, 2025

The detection of a new recombinant mpox strain in England is a reminder that the virus continues to evolve as global transmission persists. UK health officials identified the strain in a traveler returning from Asia, and genomic sequencing shows it contains genetic elements from both clade Ib and clade IIb viruses. This type of recombination signals ongoing viral adaptation and underscores the need for vigilance. Although vaccination remains effective at preventing severe disease, low uptake leaves gaps in protection. The emergence of this mixed lineage variant highlights the importance of surveillance, rapid sequencing, and international cooperation to prevent wider spread.

UK health officials warn of new mpox variant

December 8, 2025

The detection of a recombinant mpox strain in England underscores the virus’s ongoing evolution and the importance of robust genomic surveillance. The new hybrid, containing elements of clade 1b and 11b, was identified in a traveler returning from Asia, illustrating how global mobility continues to shape viral spread. While the UK Health Security Agency has emphasized that evolution is expected, the development coincides with the World Health Organization’s alert of clade 1b community transmission in multiple non-endemic countries. This convergence highlights the need for continued vigilance, equitable vaccination access, and rapid sequencing to prevent another wave of global mpox transmission.

New mpox strain identified in England

December 8, 2025

The detection of a new recombinant strain of mpox in England underscores the ongoing evolution of this virus and the global risks of continued circulation. This mixed strain, containing elements of clade Ib and clade IIb, was identified through genomic testing in a traveler returning from Asia. Health experts stress that vaccination remains the best defense, offering 75 to 80 percent protection. While the United Kingdom’s surveillance systems are robust, global inequities in vaccine access remain a major concern. As experts warn, unchecked viral spread increases the likelihood of recombination and adaptation, reinforcing mpox’s foothold as a persistent human pathogen.

England health officials identify newly evolved variant of mpox

December 8, 2025

The detection of a recombinant mpox variant in England combining elements of both clade 1 and clade 2 is a timely reminder that viral evolution is constant and surveillance remains essential. Although only one case has been identified, its emergence underscores the risks posed by global travel and the ongoing circulation of multiple clades worldwide. Health officials are right to urge vaccination among eligible groups, especially given mpox's clear patterns of spread through close physical and sexual contact. As the virus continues to evolve, rapid genomic analysis and transparent communication will be critical for early intervention and risk mitigation.

2 mpox cases confirmed in Worcester as Mass. health officials warn of ‘concerning’ uptick

December 4, 2025

The resurgence of mpox cases in Massachusetts, including two recent infections among homeless women in Worcester, highlights the persistent risks of viral transmission in vulnerable populations. Despite widespread vaccination campaigns, the Massachusetts Department of Public Health reports a concerning rise in cases since August, signaling potential gaps in prevention and surveillance. Worcester’s response—partnering with shelters and community organizations to host vaccination clinics—is a vital step toward protecting high-risk groups. However, the outbreak underscores the need for broader outreach, continued vaccination, and stigma-free public health education to prevent mpox from gaining traction among marginalized communities already facing systemic barriers to care.

Worcester confirms two cases of mpox

December 2, 2025

Worcester’s confirmation of two new mpox cases among homeless women who are sex workers underscores how social and economic vulnerability intersects with infectious disease risk. While officials stress that the public threat remains low, these cases highlight ongoing health disparities that leave marginalized populations more exposed. Coordinated monitoring by UMass Memorial Health and the Massachusetts Department of Public Health demonstrates vigilance, yet also points to the need for broader access to prevention, vaccination, and healthcare support. Addressing mpox requires more than containment—it demands compassion, equitable resources, and sustained outreach to at-risk groups often overlooked in public health planning.

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

December 1, 2025

NanoViricides’ new partnership with regulatory expert Dr. Timothy Cote and Only Orphans Cote marks a pivotal step in advancing NV-387, its broad-spectrum antiviral, toward orphan drug designation. By targeting rare and high-consequence diseases such as smallpox, mpox, and measles, the company is aligning scientific innovation with a strategic regulatory pathway that could secure market exclusivity and tax benefits. NV-387’s unique mechanism, which mimics host cell receptors to block viral entry, could make it a cornerstone of future pandemic preparedness. If efficacy is confirmed in human trials, NV-387 may redefine how the world approaches broad-spectrum antiviral defense.

Increase in Mpox cases reported in Baltimore, though risk to public remains low

December 1, 2025

Baltimore health officials have reported a rise in Mpox cases, with 24 confirmed infections so far this year, more than half occurring since September. Although the overall risk to the public remains low, the trend underscores the need for vigilance among higher-risk groups such as gay and bisexual men and those with multiple sexual partners. Clade II, the milder strain, continues to circulate in the U.S., while no cases of the more severe Clade I have been identified locally. Health authorities are urging eligible residents to get vaccinated through city clinics and primary care providers to prevent further transmission.

EU Gains Continued Access to Mpox Vaccine With New Contract

November 27, 2025

Europe’s new four-year joint procurement of up to eight million MVA-BN mpox/smallpox vaccine doses marks a long-overdue shift toward serious orthopoxvirus preparedness. With clade Ib emerging in the Democratic Republic of the Congo and evidence of local transmission among European sexual networks, the assumption that mpox was a contained 2022 event is no longer credible. The European Commission is right to treat mpox as a high-priority threat, especially given partial vaccine protection, ongoing therapeutic gaps, and rising monthly case numbers. Predictable stockpiles, targeted vaccination, and HERA-supported immunogenicity studies are essential steps—provided they are matched with sustained political attention and funding.

Recent Chicago mpox outbreak now contained, officials say

November 26, 2025

Chicago’s successful containment of its mpox outbreak shows what rapid, community-focused public health action can accomplish. After a 374% rise in cases since June and clear concentration in LGBTQ+ networks, the city activated an incident command structure, expanded vaccination access, and intensified outreach. With cases now averaging one or fewer per day, the immediate threat is low — but complacency would be premature. Most infections occurred among unvaccinated individuals, and nearly a quarter involved people living with HIV. Continued vigilance, full two-dose vaccination, and accessible clinics remain essential to preventing a resurgence and protecting Chicago’s most impacted communities.

Clade IIb Mpox Less Harmful in Infected Mice

November 24, 2025

A new study in Nature Communications has provided key insights into mpox pathogenesis, showing that clade IIb infections produce milder disease in mice than clade IIa, due to faster viral clearance and stronger immune responses. This mouse model mirrors human infection patterns, offering a valuable tool for developing antivirals and vaccines. The research underscores how viral clade differences shape disease outcomes and transmission dynamics. As mpox cases rise again in Africa, with clade Ib driving the latest emergency, the findings highlight an urgent need for continued investment in next-generation vaccines, improved surveillance, and research bridging laboratory discoveries to public health action.

Deadly mpox variant Clade 1b spreads in Europe amid rush for vaccines

November 21, 2025

Europe is now contending with the spread of the more virulent clade 1b mpox variant, a strain with fatality rates reaching 10 percent in children. The emergence of cases across ten European nations underscores a broader failure to deliver vaccines to African regions where the disease remains endemic. Experts have warned that delayed vaccination campaigns created the conditions for the virus to reemerge globally. While the European Commission has since secured up to eight million doses from Bavarian Nordic, the damage reveals a critical lesson: global health security depends on equitable prevention, not reactionary containment after predictable spread.

Mecklenburg County sees mpox surge as officials push vaccinations

November 21, 2025

The recent rise in mpox cases in Mecklenburg County is a reminder that vigilance remains essential even when overall risk is low. Seven new cases in November mark the highest monthly total in over a year, reflecting similar trends across other U.S. cities. Health officials are urging vaccination, emphasizing its protection against both Clade I and II strains and its role in preventing severe illness. As the county offers accessible vaccination clinics and walk-in services, community awareness and early prevention remain the strongest defenses. Continued public engagement and proactive health measures will help prevent small flare-ups from becoming larger threats.

Mpox cases remain elevated in New York City as officials renew vaccination push

November 18, 2025

Mpox remains a concern in New York City, where October saw 63 confirmed cases, the highest monthly count this year. Health officials report that most infections are among individuals who are unvaccinated or have not completed the two-dose JYNNEOS series. Experts emphasize that vaccination greatly reduces disease severity, even in breakthrough cases. Despite rising numbers, there is no evidence of a new, more dangerous strain circulating in the state. Public health advocates stress vigilance and vaccination rather than alarm. Continuing vaccination and awareness efforts remain the city’s best defense to prevent another major outbreak like the one in 2022.

Mpox infections in King County lead officials to again urge vaccination

November 15, 2025

The rise in mpox cases in King County this September serves as a timely reminder that the virus has not disappeared. With 46 new infections reported—the highest in three years—health officials urge continued vigilance and vaccination. While the general public remains at low risk, summer gatherings and intimate contact likely fueled the spike. Free vaccines are widely available at local clinics and pharmacies and remain the best protection against severe illness. As health authorities monitor signs of the more virulent clade I strain nearby, community awareness, vaccination, and safer behavior are essential to prevent future outbreaks and sustain local progress.

EU signs new contract to boost vaccine preparedness against mpox, smallpox

November 13, 2025

The European Union’s new joint procurement contract with Bavarian Nordic marks a major step in strengthening Europe’s pandemic preparedness. Covering up to 8 million doses of the MVA-BN vaccine for mpox and smallpox, the four-year deal builds on lessons from COVID-19 by emphasizing shared stockpiles and coordinated response. With 20 countries participating, the contract ensures equitable access, cost efficiency, and rapid deployment during future outbreaks. Led by HERA, the initiative reflects the EU’s commitment to collective health security and reduced dependency on fragmented national strategies, reinforcing Europe’s ability to respond decisively to cross-border biological threats.

Third of donated Japanese mpox vaccines going to waste in Congo amid storage challenge

November 12, 2025

Roughly one-third of Japan’s donated LC16 mpox vaccine doses in the Democratic Republic of the Congo are going to waste due to storage and handling challenges. Each vial contains 250 doses that must be used within hours once mixed, leaving little flexibility for low-turnout vaccination sessions. Despite this loss, over half a million people have been immunized, and cases in Congo are declining. The situation highlights the logistical difficulties of delivering complex vaccines in regions with fragile infrastructure and instability. Improving cold-chain systems, community mobilization, and flexible vaccination strategies will be essential to ensure that future donations reach those most in need.

Mpox infection triggers stronger, longer-term protection than vaccination, study suggests

November 11, 2025

New research published in The Lancet Infectious Diseases shows that natural mpox infection provides stronger and longer-lasting immunity—up to two years—compared with vaccination using Jynneos, whose protection declines over time. Researchers from Belgium and the Netherlands found that post-infection antibody levels were significantly higher than those generated by vaccination, highlighting the need for targeted booster campaigns to sustain population immunity. The study also confirmed no long-term viral shedding in recovered patients. Experts emphasize the importance of next-generation vaccines focused on antigens that trigger durable, cross-protective immune responses, particularly for low-resource regions facing repeated outbreaks.

How the mpox vaccine has changed lives – and minds – in Kinshasa

November 10, 2025

In Kinshasa, where the memory of mpox’s devastating peak remains vivid, a year-long vaccination campaign has transformed fear into trust. Despite logistical hurdles and limited supplies, more than 450,000 people have been immunized, thanks to collaboration between the Ministry of Health, WHO, Gavi, and community health workers. Survivors’ testimonies and visible proof of the vaccine’s effectiveness have shifted public attitudes, strengthening confidence not only in mpox prevention but in vaccination overall. Kinshasa’s response demonstrates how determination, community engagement, and transparent communication can turn crisis into resilience, creating a stronger foundation for public health and future outbreak preparedness.

Liberia Records Over 2,400 Suspected Mpox Cases as Health Ministry Launches New Vaccination and Response Drive

November 7, 2025

Liberia’s Ministry of Health has launched a 90-day national response strategy as mpox cases continue to rise across all 15 counties. Despite more than 1,100 recoveries and a low fatality rate of 0.5 percent, widespread community transmission persists, particularly in Montserrado and Nimba counties. The new plan emphasizes aggressive surveillance, treatment expansion, and public education, alongside a preventive vaccination campaign targeting high-risk populations. With 42,720 donated doses ready for rollout, officials aim to test, treat, and vaccinate efficiently while engaging communities to prevent further spread. Sustained vigilance and coordination will be crucial to achieving Liberia’s goal of zero preventable mpox deaths.

County Encourages Vaccinations for Hepatitis A and Mpox

November 7, 2025

Public health officials in San Diego County are urging residents to get vaccinated as cases of Hepatitis A and Mpox rise. Three Hepatitis A cases, including two hospitalizations, and 14 new Mpox infections highlight the growing concern. Vaccination remains the most effective protection for both diseases. Health officials emphasize hygiene, early vaccination, and awareness, particularly for at-risk groups such as men who have sex with men, people experiencing homelessness, and drug users. The County offers free vaccines at public health centers and clinics. Prevention through vaccination, hygiene, and early medical attention remains critical to halting further spread of both infections.

Mpox infections climb again in Chicago area, health officials say

November 7, 2025

Mpox cases are rising again in Chicago, with 13 new infections reported in a single week and Latino and gay or bisexual men most affected. Health officials warn that waning public attention could allow the virus to spread further. While the overall risk remains low, Clade I mpox detected in California highlights the threat of stronger strains emerging locally. Vaccination remains the most effective defense, yet many have not completed the two-dose series. Free vaccine clinics across Chicago provide easy access. Continued vigilance, community outreach, and equitable healthcare access are essential to preventing mpox from regaining a foothold in the city.

Riverside County Sees Uptick in Mpox Cases Ahead of Large Valley Events

November 5, 2025

Riverside County’s sharp rise in mpox cases, with more than half reported in just the last two months, underscores that the virus remains a pressing local health concern. As Pride celebrations begin, health officials are emphasizing prevention through vaccination and education. Completing the two-dose mpox vaccine series is key to reducing transmission, especially for those at higher risk. Free vaccination and testing at Palm Springs Pride and other county clinics make prevention accessible. The message is clear: vigilance, vaccination, and open communication are essential to protect community health and prevent a resurgence of mpox in Southern California.

Patients With Mpox Face Racial Inequities and Delays in Tecovirimat Initiation

November 4, 2025

A new study published in Clinical Infectious Diseases exposes troubling racial inequities and treatment delays among mpox patients who received tecovirimat during New York City’s 2022 outbreak. Black patients were significantly more likely to experience delayed access to treatment and hospitalization, even after accounting for HIV status and insurance. Although most patients improved with tecovirimat, systemic barriers in access and care persist. These findings underscore that public health responses must extend beyond antiviral distribution to address structural inequities in healthcare delivery. Ensuring equitable access to diagnostics, timely treatment, and follow-up care is essential for achieving true outbreak preparedness.

Global Mpox Cases Decline, but WHO Urges Vigilance as Clade Ib Circulates Beyond Africa

November 3, 2025

The World Health Organization’s latest global mpox assessment highlights both progress and peril. Although global infections have declined, clade Ib transmission is now established outside Africa, raising concerns about undetected spread. Africa remains the epicenter, with over 39,000 confirmed cases and 178 deaths, while new outbreaks in Kenya and Liberia show ongoing vulnerability. WHO warns that waning immunity, funding cuts, and stigma could reverse hard-won gains. Sustained surveillance, targeted vaccination, and integration with HIV and STI services are essential to containing the evolving virus. The decline in cases must not breed complacency as mpox adapts and expands its global reach.

Home-Based Care: A COVID-19 Era Strategy Helps Fight Mpox

November 3, 2025

As mpox continues to affect 26 African countries, home-based care has emerged as a pragmatic solution for managing mild cases amid limited hospital capacity. Adapted from COVID-19 strategies, the approach balances practicality with risk, relying on community health workers, infection prevention kits, and nutrition support to prevent household transmission. Countries such as Sierra Leone have shifted between home and institutional care depending on outbreak intensity. While over one million people have been vaccinated, vaccine access and logistics remain significant barriers. The Africa CDC’s coordinated response underscores how innovation, community engagement, and cross-sector partnerships can strengthen resilience against evolving epidemics.

Mpox Remains a Moderate Health Risk for Certain Men

November 2, 2025

The World Health Organization’s 59th situation report confirms that all clades of monkeypox virus continue to circulate globally, with Africa remaining the epicenter of infections. More than 80% of September’s 3,135 confirmed cases and 12 deaths occurred on the continent. While community transmission of clade Ib is expanding, WHO assesses the global risk as moderate for men who have sex with men and low for the general population. Ongoing vaccination campaigns in the Democratic Republic of the Congo have delivered more than 684,000 JYNNEOS and 118,000 LC16 doses. Sustained funding, dose-sparing strategies, and equitable vaccine access remain critical to control.

US public health officials vigilant as newer mpox variant detected

November 1, 2025

The emergence of community transmission of the new Clade Ib mpox variant in California and parts of Europe is a warning that global vigilance cannot wane. Though the general risk remains low, these cases—unlinked and locally acquired—suggest silent spread. The variant, first detected in the Democratic Republic of the Congo, appears to infect both men and women equally, unlike earlier outbreaks. Experts stress that vaccines reduce severity but may obscure detection as symptoms become milder. With weakened public health systems and reduced international aid, proactive surveillance, wastewater monitoring, and equitable vaccine access are essential to prevent another uncontrolled outbreak.

Bavarian Nordic signs EU smallpox and mpox vaccine contract for up to 8 million doses

October 31, 2025

Bavarian Nordic’s new four-year contract with the European Commission marks a critical step in reinforcing Europe’s pandemic and biosecurity preparedness. The deal allows EU, EEA, and Western Balkan countries to purchase up to eight million doses of the company’s smallpox and mpox vaccine, with 1.1 million already secured. By including provisions for low-income country donations, the agreement strengthens both regional and global solidarity against infectious threats. As mpox cases decline worldwide, the continued investment in vaccine access highlights the EU’s strategic recognition that public health security is inseparable from resilience, ensuring readiness for future outbreaks and biological emergencies.

Former CDC official on new mpox cases and current federal resources

October 30, 2025

Recent detections of clade I mpox in California, all requiring hospitalization and unlinked to travel, highlight the growing threat of more severe infections amid shrinking federal public health funding. Former Centers for Disease Control and Prevention official Dr. Demetre Daskalakis and Human Rights Campaign policy advocate Matthew Rose warn that budget cuts and a potential government shutdown could undermine testing, surveillance, and vaccine access. Both emphasize the importance of maintaining vaccination efforts among at-risk groups, including men who have sex with men and sex workers. Without sustained resources and coordination, the United States risks losing ground in preventing future mpox outbreaks.

Environmental surveillance as a sentinel for emerging outbreaks: Lessons from mpox in Africa

October 30, 2025

The ODIN-Mpox initiative demonstrates how environmental surveillance can revolutionize epidemic preparedness in Africa. By integrating wastewater genomics with real-time public health response, the project identifies mpox outbreaks—even in remote, non-sewered communities—days or weeks before clinical cases emerge. African-led, EU-supported, and One Health–oriented, ODIN-Mpox strengthens laboratory capacity, trains local scientists, and links surveillance directly to policy and outbreak response. Its success underscores that genomic early warning is not optional but essential infrastructure. To prevent future zoonotic crises, governments and donors must embed environmental surveillance into national preparedness plans, ensuring sustainable, equitable, and actionable epidemic intelligence across the continent.

Recent California mpox cases spur vaccine push for high-risk people

October 29, 2025

California’s first locally acquired cases of clade I mpox mark a critical juncture in U.S. public health preparedness. Unlike the 2022 outbreak strain, clade I causes more severe illness, and all recent infections occurred in unvaccinated individuals. Health officials, led by Dr. Erica Pan, are urging high-risk communities—particularly men who have sex with men and those eligible for PrEP—to complete both doses of the Jynneos vaccine. While there is no evidence of widespread transmission, the emergence of community-acquired cases underscores an urgent need for vigilance, vaccination, and proactive outreach to prevent further spread of this more virulent mpox strain.

IOM Ramps Up Ebola and Mpox Response in Africa

October 28, 2025

The International Organization for Migration (IOM) is reinforcing Africa’s health security infrastructure as new Ebola cases emerge in the Democratic Republic of the Congo and mpox remains a concern across the region. Operating at 90 border points in 15 countries, IOM’s work—ranging from surveillance and workforce training to risk communication—underscores how mobility and disease prevention intersect. With Ebola and mpox highlighting the vulnerabilities of high-mobility corridors, IOM’s coordinated, cross-border approach is essential. The organization’s proactive response exemplifies how investing in preparedness, not just crisis management, is vital to safeguarding both travelers and border communities across Africa’s interconnected regions.

Urgent warning over rise in deadlier mpox cases in Europe and US as UK officials fear virus may be spreading undetected

October 28, 2025

The UK Health Security Agency (UKHSA) is urging eligible individuals—especially gay and bisexual men—to get vaccinated as the more severe clade 1b strain of mpox spreads across Europe and the U.S. While UK cases remain travel-linked, community transmission abroad signals potential undetected global spread. Clade 1b, which has caused miscarriages and higher fatality rates in Africa, presents new risks that demand vigilance. With no direct treatments available, vaccination remains the strongest defense. Public health preparedness, timely immunization, and open communication with affected communities are critical to preventing another wave of this painful and stigmatized disease.

What is Mpox and why are cases rising in Europe?

October 27, 2025

UK health officials are sounding the alarm as a new strain of mpox, “clade Ib,” shows signs of spreading across Europe. Although infections remain few, the emergence of this variant highlights the ongoing vulnerability of sexual networks, particularly among gay, bisexual, and other men who have sex with men. The UK Health Security Agency is urging vaccination, emphasizing that existing vaccines—while untested against clade Ib—are expected to provide protection. With major Pride events approaching, vaccination is both a personal safeguard and a collective responsibility to prevent another outbreak. Vigilance and proactive immunization remain the strongest tools against mpox resurgence.

Mpox warning issued in UK after cases spread in Europe

October 27, 2025

UK health authorities are calling on eligible individuals—particularly gay, bisexual, and other men who have sex with men—to get vaccinated against mpox as a new strain, clade Ib, spreads across Europe and the U.S. Although most UK cases remain linked to travel, community transmission abroad signals growing global circulation. The UK Health Security Agency stresses that vaccination remains the best protection, even as studies on this new strain continue. With Pride season approaching and memories of 2022’s outbreak still fresh, timely vaccination and awareness can prevent resurgence and protect vulnerable communities from another painful and disruptive wave of infection.

Why new mpox cases in California are raising concerns

October 26, 2025

California’s detection of three clade I mpox cases—the first community-acquired infections of this more virulent strain in the U.S.—signals a troubling shift in the country’s post-outbreak landscape. Clade I, historically linked to higher mortality and transmissibility in Central Africa, has now surfaced domestically among unvaccinated individuals requiring hospitalization. Experts warn that underfunded federal infrastructure and a government shutdown may limit effective monitoring and coordination, leaving state health agencies to shoulder the burden. While the public risk remains low, the emergence of local transmission underscores how fragile progress can be when political instability undermines public health readiness and surveillance capacity.

Europe calls for vigilance in face of local clade 1b mpox transmission

October 24, 2025

The European Centre for Disease Prevention and Control (ECDC) has confirmed community transmission of clade 1b mpox in Europe, with five locally acquired cases across Spain, Italy, Portugal, and the Netherlands. Although symptoms were mild, the detection of this more virulent strain outside endemic regions underscores the need for vigilance. The ECDC has urged targeted prevention, including vaccination for at-risk groups, rapid testing, clade identification, and strong community engagement, particularly among men who have sex with men (MSM). With similar cases also emerging in California, Europe’s early intervention and coordinated public health response will be crucial to containing further spread.

City Health Department Expands Vaccination Efforts to Address Mpox Outbreak After 134 Cases Reported in Chicago Since June

October 24, 2025

Chicago’s mpox outbreak has climbed to more than 130 cases since June, prompting the city to intensify vaccination and outreach efforts. While the infection remains concentrated among networks of gay and bisexual men, health officials stress that anyone can contract mpox through close contact. The Chicago Department of Public Health is expanding vaccination access across community sites, bars, and colleges, emphasizing prevention and harm reduction rather than abstinence. Though most infections are mild and recovery occurs within weeks, vulnerable individuals remain at risk of severe disease. Renewed vigilance, accessible vaccines, and continued education are critical to keeping transmission under control.

First Case Of New Mpox Variant Detected In Netherlands

October 22, 2025

The confirmation of the first Clade 1b mpox case in the Netherlands marks a concerning development in Europe’s public health landscape. Detected in a man with no travel history or vaccination, the case underscores the virus’s growing ability to spread locally. Dutch authorities have acted swiftly, initiating isolation and contact tracing while emphasizing that the risk of wider transmission remains low. However, the detection of a more transmissible variant highlights the continued need for vigilance, vaccination coverage, and coordinated surveillance. As global cases rise, this incident serves as a reminder that infectious threats require sustained, science-driven preparedness and rapid response.

Will new type of mpox virus spread beyond California? Many at-risk people aren’t vaccinated.

October 22, 2025

California’s confirmation of locally transmitted Clade I mpox cases is a serious reminder that vigilance against emerging infections cannot wane. Despite widespread vaccine availability, fewer than half of at-risk individuals nationwide are fully vaccinated, leaving significant gaps in protection. The new outbreak highlights both the danger of complacency and the value of sustained public health investment, including surveillance and global cooperation. While the risk to the general public remains low, targeted vaccination and education campaigns are urgently needed. Protecting vulnerable populations through prevention and sustained funding must remain a national priority to avoid another widespread resurgence.

Officials announce first known cases of severe mpox strain spreading in US

October 17, 2025

The confirmation of locally transmitted clade I mpox in Los Angeles County marks a concerning milestone for U.S. public health. This is the first known instance of domestic spread of the more severe strain, historically confined to Central and East Africa. While officials maintain that public risk remains low, the emergence highlights the need for continued vigilance, testing, and vaccination among high-risk populations. Local health departments must strengthen contact tracing and public awareness to prevent wider transmission. As the global landscape of mpox evolves, early detection and transparent communication remain essential to containing this more virulent form of the virus.

California officials confirm 1st US case of severe mpox strain with no travel history

October 16, 2025

The first U.S. case of the more severe Clade I mpox strain without recent travel history marks a concerning shift in the virus’s domestic transmission. Detected in Long Beach, California, the case underscores the need for heightened vigilance, rapid contact tracing, and continued vaccination among at-risk groups. Although officials say the public risk remains low, the case signals that containment strategies must adapt as the virus evolves beyond imported infections. Sustained public health surveillance, early testing, and equitable access to the JYNNEOS vaccine are vital to preventing wider spread and ensuring the U.S. remains prepared for future orthopoxvirus threats.

California mpox cases raise concerns. But health officials say the risk remains low

October 16, 2025

The confirmation of two clade I mpox cases in California, without travel links, marks a potential turning point in the U.S. outbreak landscape. While health officials stress that the public risk remains low, the emergence of possible local transmission is concerning, especially given reduced federal public health capacity amid the CDC shutdown. Clade I mpox, now widespread in Africa, poses broader risks across populations compared to the milder clade II strain. Early containment and cross-agency coordination are critical to preventing sustained transmission. This event underscores the continuing need for vigilance, testing, and well-resourced public health infrastructure.

Long Beach Officials Investigate Patient with Severe Mpox Strain

October 15, 2025

The detection of a clade I mpox case in Long Beach marks a concerning milestone, representing the first known U.S. infection without travel history. While officials emphasize that public risk remains low, the emergence of this more virulent strain underscores the importance of vigilant surveillance, rapid testing, and equitable vaccine access. Health authorities’ prompt containment measures and community outreach are reassuring, yet the event highlights the need for sustained national preparedness. As global travel and viral evolution blur boundaries, this case serves as a reminder that proactive monitoring and public trust remain critical pillars of outbreak prevention and response.

Sierra Leone’s Mpox Education Campaign Offers Public Health Model

October 14, 2025

Sierra Leone’s success in sharply reducing mpox cases offers a model for effective community-driven outbreak response. Through a robust public awareness campaign using radio, posters, text messages, and market outreach, new cases fell from 600 a week in May to just 26 by September. Improved testing, vaccination, and open communication helped dispel fear and stigma while empowering residents to take preventive measures. Collaboration between the Ministry of Health, WHO, UNICEF, and local leaders demonstrates how trust and education can turn the tide of an epidemic. Sustained funding and continued vigilance will be essential to preserve these hard-won gains.

Africa Region | Mpox Appeal - Operation Update #4 (MDRS1003)

October 13, 2025

Mpox continues to challenge Africa’s health systems despite recent progress. From January to August 2025, more than 44,000 cases and 180 deaths were reported across 28 countries, with clades I and II both circulating. While July and August saw slight declines due to intensified interventions, renewed surges in Guinea, Togo, Sierra Leone, Kenya, and Malawi highlight persistent vulnerabilities. Guinea’s outbreak, with over 900 cases, shows unclear viral linkages, raising genomic surveillance concerns. The Africa CDC maintains Mpox as a continental health emergency, and WHO has reclassified it as a Grade Three outbreak, emphasizing that sustained funding, vigilance, and regional coordination remain critical.

Local Mpox Case Confirmed In Madrid

October 13, 2025

Spain has reported its first locally transmitted case of Mpox clade 1b, marking a concerning development in Europe’s ongoing struggle to contain emerging variants. Until now, all European cases of this strain had been imported, primarily from Africa. The patient in Madrid is recovering in home isolation, and contact tracing is underway. With 487 Mpox cases already recorded in Spain this year, public health vigilance remains essential. The U.S. Centers for Disease Control and Prevention emphasizes that Mpox is vaccine-preventable, highlighting the need for widespread vaccination access and continued international monitoring to prevent further community transmission of this more contagious strain.

Spike in mpox cases in Chicago prompts warning from city health officials

October 10, 2025

Chicago’s recent rise in mpox cases is a stark reminder that vigilance and vaccination remain critical. The city recorded 100 infections between July and September, primarily among men aged 18 to 64, with two hospitalizations reported. While no Clade I cases have been detected, health officials warn that Clade IIb—the strain behind the 2022 global outbreak—continues to circulate. The Chicago Department of Public Health is expanding vaccination events and urging eligible residents to complete both JYNNEOS doses. Preventing another large-scale resurgence will depend on early vaccination, community education, and sustained outreach to at-risk populations, especially within social and sexual networks.

Trial results indicate Jynneos vaccine performs well in young children

October 9, 2025

Bavarian Nordic’s announcement of positive trial results for its Jynneos (MVA-BN) mpox and smallpox vaccine in children marks a significant milestone in outbreak preparedness. Conducted in the Democratic Republic of the Congo and Uganda, the trial found that children aged 2 to 11 produced immune responses equal to or stronger than adults, with no new safety concerns. This finding is critical for regions where children are disproportionately affected by mpox. Pending regulatory approval, expanding vaccination eligibility to younger populations could strengthen disease prevention efforts and fill a crucial protection gap in global health security.

NYC mpox cases increase again in September, surpassing 2025 monthly high

October 9, 2025

New York City’s recent rise in mpox cases signals a concerning return of the virus, particularly among men who have sex with men. September’s 61 cases mark the highest monthly total of 2025, underscoring the city’s ongoing vulnerability despite previous containment efforts. Public health officials attribute the uptick to seasonal trends, yet the persistence of double-digit weekly case counts highlights the need for sustained vaccination, testing, and education. The availability of free Jynneos vaccines across 13 city sites is crucial, but renewed community engagement remains essential to prevent complacency and protect vulnerable populations from another widespread outbreak.

In Kaduna, Nigeria, all hands are on deck to fight an mpox outbreak

October 9, 2025

Kaduna’s mpox vaccination drive demonstrates the power of trust, inclusion, and community-led action in outbreak response. From retired civil servant Amos Kintaro’s cautious recovery to the enthusiasm of residents like Simon Boniface and Ibrahim Haruna, the campaign shows how accessible, free vaccines can restore confidence and health equity. Early advocacy and strong collaboration between state and federal health authorities built momentum, while community leaders helped dispel misinformation. With over 3,000 doses administered in August and a second phase underway, Kaduna’s experience stands as a model for how outreach, transparency, and compassion can overcome fear and bring diseases under control.

Clade I Mpox Detected in Pierce County, Washington, Wastewater

October 8, 2025

The detection of clade I mpox virus in Pierce County wastewater marks a significant early warning for Washington State’s public health system. While no human cases have been identified, the collaboration between the Department of Health, the University of Washington, and the Tacoma-Pierce County Health Department demonstrates proactive surveillance in action. Wastewater testing provides a critical tool for detecting emerging threats before they reach clinical settings. Ongoing monitoring, transparency, and readiness will be essential to prevent potential transmission. This discovery reinforces that vigilance and interagency cooperation remain key to containing evolving infectious diseases such as mpox.

Stronger, faster, fairer: making mpox vaccines accessible

October 7, 2025

The global mpox crisis continues to expose deep inequities in vaccine access and outbreak preparedness. While licensed vaccines like MVA-BN and LC16m8 exist, their limited availability in low- and middle-income countries leaves millions unprotected. CEPI’s mpox program aims to close these gaps by generating critical data for regulators, expanding testing capacity in high-burden countries, and accelerating vaccine deployment. Through partnerships with WHO, Africa CDC, and local research institutes, CEPI is building the scientific and logistical infrastructure needed to deliver vaccines efficiently and equitably. This work is not just about stopping today’s outbreak; it is about preparing for the next.

Bavarian Nordic Reports Positive Topline Data for Mpox/Smallpox Vaccine in Pediatric Population

October 7, 2025

Bavarian Nordic’s new clinical study marks a critical advancement in mpox prevention for children. Conducted in the Democratic Republic of the Congo and Uganda, the MVA-BN vaccine trial demonstrated that children aged 2–11 generated stronger immune responses than adults, with no unexpected safety issues. These findings pave the way for extending vaccine approval to younger populations, offering vital protection in regions hardest hit by ongoing outbreaks. With CEPI’s support, the results could transform pediatric mpox prevention and strengthen public health resilience in Africa and beyond. Pending regulatory review, this development represents meaningful progress toward broader global vaccine equity.

Kenya and Zambia battle mpox spikes as African countries manage multiple health threats

October 2, 2025

Africa’s fight against infectious diseases remains complex, as mpox trends diverge across the continent. While major hot spots like Sierra Leone show improvement, Kenya and Zambia are seeing troubling spikes, with local spread now suspected in Senegal. At the same time, cholera cases are surging in Chad, Burundi, and Angola, pushing the continent toward 300,000 cases this year. The Democratic Republic of the Congo’s Ebola outbreak offers cautious optimism with no new cases for nearly a week, but sustained vigilance is essential. The overlapping crises highlight the urgent need for stronger surveillance, community engagement, and investment in health infrastructure.

Why HHS Is Wrong to Bring Back the Stigmatizing Name Monkeypox

October 1, 2025

The World Health Organization’s 2022 decision to rename “monkeypox” as “mpox” was more than cosmetic. It reduced stigma, built trust with LGBTQ communities most affected by the outbreak, and aligned disease naming with scientific accuracy and dignity. The U.S. Department of Health and Human Services’ intent to revert to the old name undermines that progress, creating confusion among providers and patients while wasting resources already invested in outreach and education. Public health depends on clarity and credibility. Reverting to a stigmatizing and misleading name weakens both, jeopardizing trust and response at a time when consistency is critical.

America reverts to calling mpox ‘monkeypox’ in anti-woke drive

September 30, 2025

The U.S. Centers for Disease Control and Prevention’s decision to revert from “mpox” back to “monkeypox” undermines years of effort to reduce stigma and align with scientific accuracy. The term monkeypox is misleading, as rodents are the virus’s primary reservoir, and it carries racial and homophobic connotations that fueled misinformation during the 2022 outbreak. The World Health Organization recommended the neutral term “mpox” to avoid these harms. Reinstating outdated terminology risks worsening stigma, hampering public health messaging, and repeating the missteps seen during COVID-19. Language matters in science and health, and this reversal is both regressive and dangerous.

Senegal confirms RVF outbreak amid new mpox cases

September 29, 2025

Senegal is contending with a dual public health challenge: a deadly Rift Valley Fever outbreak in Saint-Louis and a fresh resurgence of Mpox. With 21 RVF cases and seven deaths, the government has mobilized insecticide campaigns and community surveillance to curb mosquito transmission. At the same time, newly confirmed Mpox cases highlight how quickly the virus can resurface, with two unrelated clusters now under investigation. Authorities are monitoring dozens of contacts while reinforcing public awareness and clinical preparedness. Senegal’s situation demonstrates the importance of rapid, multi-pronged responses when simultaneous epidemics strain resources and demand strong community engagement.

Monkeypox traces found in Pierce County wastewater, no active cases confirmed

September 26, 2025

The detection of mpox in Washington State wastewater highlights the vital role of surveillance systems in protecting communities. While no human cases of Clade 1 mpox have been confirmed in Pierce County, this finding underscores the importance of vigilance. Wastewater testing allows early identification of potential risks before widespread illness emerges. Health officials emphasize that the risk remains low, but they urge individuals with symptoms to seek care and avoid close contact. With vaccines available for those at higher risk, this is a timely reminder that proactive monitoring and community awareness are essential tools in preventing outbreaks.

Doctors urge vaccinations amid uptick in mpox cases in Chicago area

September 22, 2025

Chicago is seeing a rise in mpox cases, sparking concern among health officials and community leaders. Since June, 83 cases have been reported, with nearly one-third appearing in the last two weeks. While numbers remain well below the city’s 2022 peak, the persistence underscores the need for vigilance. Vaccination remains the strongest defense, with data showing that fully vaccinated individuals experience milder illness. Doctors emphasize that while anyone can contract mpox, gay men and transgender women remain at higher risk. With no curative treatment available, prevention through vaccination and isolation of cases is critical to limiting further spread.

Chicago sees rise in mpox cases in recent months, health officials say

September 22, 2025

Chicago is experiencing a sharp increase in mpox cases, with 67 infections reported since late June compared to just 11 in the previous three months. Health officials warn that the virus, known for its painful rash and flu-like symptoms, poses greater risks for immunocompromised individuals and those with underlying health conditions. The Chicago Department of Public Health urges residents at higher risk to complete the two-dose vaccination series, the strongest available protection. With transmission occurring through close contact, shared materials, or respiratory droplets, the city’s rising case numbers underscore the urgent need for vigilance, vaccination, and community responsibility.

Riverside County Reports New MPOX Case Linked to International Travel; Health Officials Urge Vaccination

September 18, 2025

Riverside County’s confirmation of a new mpox case linked to international travel underscores the ongoing global nature of this virus. Although the patient is recovering and no longer infectious, the strain involved is more severe, highlighting the need for vigilance. Public health officials emphasize vaccination for travelers and those engaging in close contact abroad, alongside awareness of symptoms such as fever, rash, and swollen lymph nodes. With nine cases reported in 2025 compared to 41 last year, prevention remains key. Proactive measures, including vaccination and transparent health communication, are vital tools in protecting communities from future mpox spread.

LGBTQ-friendly states led US in mpox vaccination uptake, study shows

September 18, 2025

A new study highlights how policy environments directly shape health outcomes. During the 2022–2023 mpox epidemic, U.S. states with strong LGBTQ+ equality laws had vaccination rates four times higher than states with weaker protections. Because vaccines were free nationwide, financial access was not the main barrier. Instead, stigma and mistrust of healthcare in less inclusive states likely suppressed uptake. Researchers emphasize that equitable laws can foster trust and improve public health responses. Strengthening LGBTQ+ protections is not only a matter of civil rights but also a vital strategy for ensuring faster, broader uptake of lifesaving interventions during epidemics.

How Mpox revealed an epidemic of untreated HIV in Sierra Leone – as Trump’s aid cuts begin to bite

September 16, 2025

Sierra Leone’s Mpox outbreak has exposed a deeper health crisis: untreated HIV. For patients living with HIV without access to medication, Mpox becomes deadly, as Dr Elin Hoffman Dahl’s heartbreaking account illustrates. Despite strong progress in case management, vaccination, and surveillance, gaps remain. Trump-era aid cuts stripped away flexible funding that once enabled rapid responses, slowing Sierra Leone’s efforts and straining resources for HIV and TB. While local leadership has stepped up, inequities in vaccine access and persistent HIV stigma undermine progress. Sierra Leone’s experience highlights the urgent need for sustained global support alongside stronger, African-led health systems.

Prolonged mpox cases more likely to occur in Black and HIV patients, study suggests

September 15, 2025

A new California study highlights troubling disparities in mpox outcomes, showing that Black patients and people with HIV were more likely to experience prolonged infections lasting 28 days or more. Published in Emerging Infectious Diseases, the analysis found that protracted cases carried higher hospitalization rates, especially among those with lower CD4 counts or not engaged in HIV care. Notably, no prolonged cases occurred in fully vaccinated patients. These findings emphasize the urgent need for targeted vaccination campaigns, education, and outreach to vulnerable groups. Addressing inequities in care and prevention remains essential to reducing the burden and risks of mpox.

Mpox cases continue to climb in New York City

September 12, 2025

New York City is seeing another seasonal rise in mpox, with 57 new cases between Aug. 10 and Sept. 11, the highest monthly total so far in 2025. While the numbers remain far below the explosive 2022 outbreak, officials warn that the virus persists, mainly affecting gay and bisexual men, men who have sex with men, and transgender people. Vaccination remains the most effective tool for prevention, yet access challenges remain since the vaccine moved to the commercial market. City health officials urge those at risk to get the two-dose series and to seek care immediately if symptoms appear.

In 2022, the name 'monkeypox' was nixed. Now the U.S. is reviving it

September 12, 2025

The World Health Organization renamed monkeypox as mpox in 2022 to reduce racist and stigmatizing associations, reflecting both scientific accuracy and respect for affected communities. Now, the U.S. government has quietly reverted to the old name, sparking confusion and criticism from clinicians and researchers. Experts warn that returning to “monkeypox” undermines years of public health progress, revives harmful stereotypes against Black and LGBTQ+ people, and risks distracting from urgent response needs. Words matter in health communication. Reverting to stigmatizing terminology risks eroding trust, deepening divisions, and weakening the global unity required to combat mpox outbreaks effectively and compassionately.

US government signs $56 million deal for smallpox/mpox vaccine

September 10, 2025

Emergent BioSolutions’ $56 million contract extension to supply ACAM2000, a combined smallpox and mpox vaccine, highlights the U.S. government’s continued investment in biodefense preparedness. ACAM2000, first licensed in 2007 for smallpox and expanded in 2024 to cover mpox, joins Jynneos as one of only two FDA-approved vaccines for these threats. The agreement, part of a 10-year contract with ASPR, ensures doses will be delivered to the Strategic National Stockpile. As mpox cases persist globally and smallpox remains a bioterrorism concern, sustained partnerships between government and industry remain essential to bolstering public health readiness against high-consequence viral threats.

New Mpox vaccine study to launch in outbreak-affected DRC

September 10, 2025

The Democratic Republic of the Congo is set to launch groundbreaking research on the LC16m8 mpox vaccine, supported by CEPI and international partners. This study will provide the first real-world African data on vaccine safety and effectiveness, including in children, amid the ongoing public health emergency. Three million LC16m8 doses donated by Japan will be deployed, with monitoring in hotspot health zones of Équateur province. The trial represents a milestone for Africa in building evidence-based vaccination strategies and strengthening research capacity. Its findings could inform global policy, ensuring better protection for vulnerable populations and reinforcing preparedness against future outbreaks.

With mpox infections rising in Chicago, health officials urge vaccination

September 10, 2025

Chicago’s recent summer spike in mpox cases is a clear reminder that vigilance and vaccination remain essential. With 83 percent of this year’s cases reported since June and nearly half among unvaccinated individuals, public health officials are emphasizing prevention. Festivals and large gatherings have been linked to transmission, especially among gay, bisexual, and same-gender-loving men with multiple or anonymous partners. Vaccination is free and effective, yet uptake lags. Public health leaders urge residents to complete the two-dose series, remain alert to symptoms, and seek testing quickly. Community protection requires both personal responsibility and sustained public health engagement.

IOM Expands Support to Contain Mpox Threat in West and Central Africa

September 9, 2025

The International Organization for Migration (IOM) is stepping up its role in the Mpox response across West and Central Africa, focusing on vulnerable border regions where mobility, porous boundaries, and weak health systems heighten risk. By reinforcing surveillance, training border responders, and deploying community agents, IOM ensures mobile populations are not excluded from care. Strategic mapping in Sierra Leone, screenings in Guinea, and volunteer training in Togo exemplify how targeted interventions protect both travelers and host communities. Yet with only 10 percent of its funding appeal met, urgent donor support is needed to sustain these critical, mobility-sensitive health systems.

Mpox no longer an international health emergency, says WHO chief

September 5, 2025

The World Health Organization has declared that mpox no longer represents a Public Health Emergency of International Concern, marking a major milestone in the global response. Sustained declines in cases in the Democratic Republic of the Congo, Burundi, Sierra Leone, and Uganda informed this decision. While the announcement reflects clear progress, it should not be mistaken for eradication. Mpox continues to pose risks in vulnerable populations and under-resourced areas. The decision underscores the value of international cooperation and targeted interventions, while reminding the global community that vigilance, investment in surveillance, and equitable vaccine access remain essential to prevent resurgence.

Mpox Still a Continental Emergency, Africa CDC Advisory Group Recommends

September 4, 2025

The Africa CDC’s Emergency Consultative Group has recommended that the Public Health Emergency of Continental Security (PHECS) for mpox remain in place, despite recent declines in cases. While weekly confirmed infections fell by 52 percent between May and August 2025, new surges in Ghana, Liberia, Kenya, and Zambia highlight the fragility of progress. Infant deaths, case fatality rates above one percent in several countries, and gaps in testing and vaccine access underscore persistent risks. The Group warned that lifting the PHECS prematurely could weaken political will and resources. Sustained vigilance, expanded vaccination, and stronger surveillance remain essential to prevent resurgence.

Mpox Resurgence: A Global Wake-Up Call for Zoonotic Disease Preparedness

September 4, 2025

The resurgence of mpox highlights the fragility of global health security. Once primarily linked to zoonotic spillovers in Central and West Africa, the virus is now sustained through human-to-human transmission across more than 100 countries. A recent review underscores how waning smallpox immunity, ecological disruption, and inequitable vaccine access fuel its spread. Vulnerable groups—immunocompromised individuals, pregnant people, and children—remain at highest risk of severe outcomes. While tools like MVA-BN vaccines and antivirals exist, their uneven distribution threatens to entrench mpox. The lesson is clear: without equity, sustained investment, and One Health approaches, regional outbreaks will continue to spark global crises.

Two Years On: MVA-BN Vaccine Still Shields Against Severe Mpox, But Equity and Boosters Loom as Next Frontiers

September 3, 2025

A new study in The Lancet Primary Care offers the strongest evidence yet that the MVA-BN vaccine provides durable protection against severe mpox more than 18 months after vaccination. Australian researchers found full vaccination reduced hospitalization risk by 89 percent, despite antibody levels waning within months. Breakthrough infections were milder, underscoring the vaccine’s continued clinical value. The absence of outcome data for HIV-positive individuals remains a critical gap, especially as outbreaks intensify in high-prevalence regions. Policymakers now face key questions: whether booster doses are needed, how to prioritize high-risk populations, and how to ensure global equity in vaccine access.

Mpox still present in Virginia, as VDH tracks multiple cases in the commonwealth

September 3, 2025

Mpox, first detected in Virginia during the 2022 outbreak, continues to persist even as case numbers remain lower than in the initial surge. The Virginia Department of Health reports 23 cases so far in 2025, nearly matching the total for all of 2024. Transmission occurs primarily through close or sexual contact, with rashes serving as the most identifiable symptom. Men account for 95 percent of cases, and individuals with HIV or other immunocompromising conditions are most vulnerable to severe outcomes. Public health officials stress vaccination, especially for those with multiple partners, to reduce risk and protect communities across the commonwealth.

Three powerful antibodies discovered with potential to treat mpox

September 3, 2025

Researchers at Mount Sinai have identified three monoclonal antibodies that block mpox viral spread and prevent severe disease. Published in Cell, the study shows that these antibodies, isolated from a recovered patient, target the conserved viral protein A35, halting infection in lab models and fully protecting rodents. Importantly, individuals recovering from mpox naturally produce these antibodies, and their presence correlates with milder illness and fewer hospitalizations. With no approved drugs for mpox and failed clinical trials of existing candidates, this discovery offers a promising pathway toward targeted therapies that could address urgent global health and biodefense needs.

Whatever happened to mpox? Is it still a threat?

September 2, 2025

Mpox remains a global health emergency nearly a year after Africa CDC and WHO issued their highest alerts, yet the disease has faded from headlines. In Kenya and across Africa, the virus has spread widely, with over 100,000 suspected cases this year. Despite $1.1 billion in pledged support, vaccine delivery has lagged, with many U.S.-donated doses now expired. Experts warn that inconsistent data, weak surveillance, and funding cuts leave the world “walking blind.” Progress in lab capacity and vaccine approvals offers hope, but the sluggish response risks entrenching mpox as a permanent threat with global consequences.